abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Esta página no está disponible en Español y está siendo mostrada en English

Respuesta de la empresa

23 Nov 2015

Autor:
Novo Nordisk

Novo Nordisk statement

We support a mandatory reporting mechanism for European companies that manufacture or contract to manufacture products containing 3TG necessary to product functionality or manufacture.  The reporting mechanism should mirror the US Securities and Exchange Commission requirements to ensure a consistent international framework.